Cite

HARVARD Citation

    Hampel, P. et al. (2022). Combined ibrutinib and venetoclax for treatment of patients with ibrutinib‐resistant or double‐refractory chronic lymphocytic leukaemia. British journal of haematology. pp. 239-244. [Online]. 
  
Back to record